What Will Happen to Interpace Diagnostics Group Inc (NASDAQ:IDXG) Next? The Stock Has Decline in Shorts

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Logo

The stock of Interpace Diagnostics Group Inc (NASDAQ:IDXG) registered a decrease of 2.31% in short interest. IDXG’s total short interest was 1.51M shares in September as published by FINRA. Its down 2.31% from 1.54 million shares, reported previously. With 280,500 shares average volume, it will take short sellers 5 days to cover their IDXG’s short positions.

The stock increased 1.12% or $0.0087 during the last trading session, reaching $0.785. About 128,426 shares traded. Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) has declined 20.91% since September 13, 2018 and is downtrending. It has underperformed by 20.91% the S&P500.

Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. The company has market cap of $29.97 million. The firm offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its proprietary PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy; and ThyraMIR, which assesses thyroid nodules for risk of malignancy utilizing a proprietary gene expression assay. It currently has negative earnings. The Company’s clients consist primarily of physicians, hospitals, and clinics.

More notable recent Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) news were published by: Nasdaq.com which released: “Health Care Sector Update for 01/25/2019: AZN,IDXG,ABBV – Nasdaq” on January 25, 2019, also Globenewswire.com with their article: “Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019 – GlobeNewswire” published on May 06, 2019, Globenewswire.com published: “Interpace Diagnostics Enters into Agreement with Renowned Integrated Health System – GlobeNewswire” on October 04, 2018. More interesting news about Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) were released by: Nasdaq.com and their article: “Predictive Oncology Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update – Nasdaq” published on August 19, 2019 as well as Globenewswire.com‘s news article titled: “Interpace Diagnostics Announces First Independent Publication Demonstrating Clinical Utility of BarreGENĀ® – GlobeNewswire” with publication date: February 19, 2019.

Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.